BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on April 3 and set a price target of ...

StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating ...

PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...

BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million during the quarter, compared to analysts’ expectations of $711.05 million.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...